Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool March 21, 2011 Brian Orelli	Let's See Some Data, Curis Curis investors seem to have shrugged off the multiple unknowns and embraced the potential for the company's skin cancer drug.
BusinessWeek June 13, 2005 Catherine Arnst	Biotech, Finally The past 30 years of biological discoveries, insights into the human genome, and exotic chemical manipulation have unleashed a wave of biological drugs, many of them reengineered human proteins.
The Motley Fool July 12, 2010 Ryan McBride	Synta Pharma CEO Trumpets New Top Cancer Drug Synta Pharmaceuticals has been climbing back from one of the Boston area's highest-profile clinical trial failures of 2009.
The Motley Fool March 3, 2009 Brian Orelli	A Tale of 2 Weeks It's been a busy two weeks at Genzyme as two nasty notes from the FDA follow two approvals.
The Motley Fool July 15, 2010 Ryan McBride	Glaxo's Tempero Pharma Advances on Hot Niche of Immunology Staking claim in emerging fields.
The Motley Fool March 3, 2011 Ryan McBride	With Sanofi Buyout of Genzyme, Rare Disease Execs Upbeat About Interest in Their Niche The field might benefit from the increased interest in it among pharmaceutical players.
The Motley Fool March 15, 2005 Charly Travers	The Best Company I've Never Owned The history of Genentech's Avastin, which just completed another phase 3 clinical trial showing that Avastin is effective in the treatment of non-small cell lung cancer. The author laments missing the opportunity to invest.
The Motley Fool August 9, 2010 Jim Mueller	3 Stocks to Play Biotech Three promising ideas for investing in this exciting area.
BusinessWeek August 26, 2010 Tom Randall	Cocktails Are Next For Cancer-Drug Makers Taking a cue from the cocktails of drugs that have made AIDS survivable, drugmakers are pursuing combination therapies against cancer.
The Motley Fool November 29, 2011 Brian Orelli	Winners and Losers of Roche's Avastin Woes What the FDA giveth, the FDA can taketh away.
The Motley Fool April 26, 2004 Alyce Lomax	Genentech's Lucky Day Genentech and OSI Pharmaceuticals jump in today's trading session after favorable trial results for a cancer drug.
The Motley Fool November 2, 2004 Charly Travers	Biotech's 5-Baggers: Part 3 Year after year, the hottest biotech companies with investors are those with drugs in development for the treatment of cancer.
The Motley Fool March 1, 2007 Brian Lawler	Know Your Drug Stock ABCs: Part 2 Investing in the pharmaceutical and biotechnology industries can be difficult. Here are terms investors should know to better understand how the clinical trial process involved with bringing a drug to market works.
The Motley Fool September 7, 2007 Brian Orelli	Merck Says No to This Protein An FDA advisory panel recommends unanimous approval of a new HIV drug from Merck. The new class of HIV medications fight the virus by blocking one key protein from entering cells.
The Motley Fool December 31, 2008 Brian Orelli	Health Care's Golden Children The whole industry wasn't down this year.
Registered Rep. February 1, 2005 Bob Hirschfeld	Healing Investments New lung cancer drugs mean good news in both the doctor's office and on Wall Street.
The Motley Fool August 9, 2010 Luke Timmerman	Kaleetan Seeks to Stand on Dendreon's Shoulders Kaleetan Pharmaceuticals tries to improve upon Dendreon's breakthrough cancer drug.
BusinessWeek April 30, 2007 Catherine Arnst	Teaching The Body To Fix Itself Cancer vaccines still in trial stages may be able to prolong life with few side effects, but the FDA has yet to be convinced.
The Motley Fool February 27, 2004 Alyce Lomax	Genentech's Hope For the past two days, Genentech has been an example of what many investors hinge their hopes and dollars on. Yesterday's FDA approval of the company's groundbreaking cancer drug, Avastin, was the reason positive sentiment remained infectious today.
The Motley Fool April 27, 2011 Brian Orelli	Falling Into the Zaltrap Lung cancer out, colon cancer in phase 3 clinical trial for Regeneron Pharmaceuticals' new drug.
BusinessWeek May 9, 2005 Catherine Arnst	Genentech's Lessons For Big Pharma The biotech company focuses on science -- not marketing, acquisitions, or patents.
The Motley Fool February 16, 2010 Brian Orelli	For Blockbuster Cancer Drugs, Approvals Are the Easy Part Don't get too excited. As an investor, you can lower your risk by investing in cancer drug companies after a clinical trial success but before an FDA approval, but you'll also reduce your reward.
The Motley Fool May 21, 2007 Mike Havrilla	Allos Aligned for Success With two drugs that both sport reasonable chances of positive clinical data and FDA approval, biotech investors should take a look at Allos -- before any potential good news rolls in.
The Motley Fool June 7, 2011 Brian Orelli	Sometimes a Partnership Feels Personal Merck and Roche hook up for a diagnostic drug deal.
BusinessWeek January 8, 2007 Catherine Arnst	Decoding Alzheimer's After a century, promising treatments at last - and whispers of a cure.
The Motley Fool July 31, 2007 Brian Orelli	GPC Takes a Pit Stop The biotech company pulls its New Drug Application for Satraplatin. There is something twisted about having to wait to get a drug to market because it's performing better than expected. Investors, take note.
The Motley Fool March 30, 2010 Brian Orelli	Invest in This Space at Your Own Risk Lung cancer is a tough foe for drugmakers.
BusinessWeek May 27, 2010 Pettypiece & Gibson	Training the Immune System to Fight Cancer Bristol-Myers' new melanoma drug may be a "game changer."
BusinessWeek March 8, 2004 Arlene Weintraub	And When ImClone's Drug Doesn't Work... Physicians have greeted ImClone Systems Inc.'s (IMCL ) cancer drug, Erbitux, with a mixture of glee and grim realism. The drug dramatically shrinks colon tumors in some patients. But in others, it has little effect -- and no one knows why.
The Motley Fool January 29, 2008 Brian Lawler	Genentech Adds to Avastin's Arsenal Genentech's lead drug Avastin gains another use -- just not the one investors expected.
The Motley Fool October 8, 2010 Luke Timmerman	Onyx Delays Cancer Drug Application As FDA Asks for More Data Shares fell about 7% in after-hours trading Thursday evening.
The Motley Fool June 21, 2011 Brian Orelli	Data Look Good, Approval Unknown Accelerated approvals are like that. The data should give Curis' investors added confidence that vismodegib works, but whether it can get approved with this limited data remains to be seen.
The Motley Fool April 5, 2010 Brian Orelli	1 Month to Go! Is Dendreon a Buy? Only if you understand the risks.
The Motley Fool May 14, 2010 Ryan McBride	Genzyme in "Tough Spot" With Icahn Proxy Challenge Carl Icahn is pushing for change, but Genzyme's CEO has been pushing back.
The Motley Fool November 20, 2007 Brian Orelli	Explaining Onyx Pharmaceuticals' Sell-Off The FDA approved Nexavar as a treatment for liver cancer, but the good news causes a sell-off of the stock.
The Motley Fool October 27, 2010 Ralph Casale	Companion Diagnostics in Cancer Drug Development Diagnostic companies partnering with drug developers can make for an attractive investment segment.
The Motley Fool October 9, 2006 Brian Lawler	Much-Needed Publicity for Millennium Millennium Pharmaceuticals' cancer-fighting drug Velcade is set to gain exposure for a new treatment. Investors, take note.
Investment Advisor December 2005 Greg B. Scott	Buying The Future Prudent investing in biotechnology can offer great returns for clients. It's also the wave of the future. Armed with a basic understanding of the dynamics of the industry and the valuation inflection points, intelligent investors can make significant returns.
The Motley Fool July 30, 2007 Brian Orelli	Another Blow to Gene Therapy The FDA shuts down a clinical trial, tripping up Targeted Genetics and possibly its competitors. A subject in the trial of their gene therapy arthritis medication died shortly after taking the drug.
The Motley Fool March 27, 2009 Brian Orelli	Trading Up With the $95 From Genentech Genentech is gone; here's what you should replace it with.
The Motley Fool September 23, 2010 Ryan McBride	Genzyme Boss Not Ready to Sell to Sanofi The Dutch-born CEO is known for his tight control of decisions made at Genzyme, even to a fault.
The Motley Fool November 18, 2008 Brian Orelli	Genzyme Grounded for Thanksgiving The biotech won't get a decision on Myozyme until February.
The Motley Fool January 27, 2006 Stephen D. Simpson	A Real Triumph for Alexion A powerful clinical result brings FDA approval into sight for this biotech company. Investors, enjoy the day -- this is what makes biotech investing fun and exciting.
The Motley Fool May 3, 2005 Charly Travers	PDL's Well-Stocked Pipeline A broad drug portfolio makes this biotech, Protein Design Labs, a long-term winner.
The Motley Fool August 27, 2010 Brian Orelli	Down 35%! This Just Shouldn't Happen Someone's to blame and it isn't ImmunoGen.
The Motley Fool October 8, 2007 Charly Travers	Scanning 4 Biotechs There are major events set for the following biotech companies during this quarter. Investors, take note: BioMarin Pharmaceutical... Exelixis... Neurocrine Biosciences... Pain Therapeutics...
The Motley Fool June 4, 2007 Brian Orelli	OXiGENE's Moving Ahead The drug maker reaches a deal with FDA on its lead compound. Investors, take note.
The Motley Fool April 19, 2004 Charly Travers	4 Promising Biotech IPOs Several recently gone-public biotechs boast surprisingly interesting drug pipelines. From drugs for hepatitis to hopeful cancer treatments, watch out for these four biotech debutantes. If trials go smoothly, they may be the next up-and-coming stocks in the industry.
The Motley Fool January 26, 2009 Brian Orelli	Which One of These Is Not Like the Other? Bristol-Myers and Eli Lilly run into some comparability issues.
The Motley Fool July 9, 2008 Brian Lawler	Predicting More Good News From Invitrogen Invitrogen gets a positive review from the FDA for one of its tests.